Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Regeneron, Sanofi Amend Antibody Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Regeneron, Sanofi Amend Antibody Alliance

Sanofi to gain global rights to Kevzara and sole ex-U.S. rights to Praluent, Regeneron to gain sole U.S. rights to Praluent

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron Pharmaceuticals, Inc. and Sanofi have amended their antibody collaboration for Kevzara (sarilumab) and Praluent(alirocumab) by restructuring into a royalty-based agreement. Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent.
 
Under the proposed terms of the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories. These changes are part of an effort to increase efficiency and streamline operations for the products. The existing collaboration relating to Dupixent (dupilumab) remains unchanged. Completion of the proposed agreement is expected to be finalized in 1Q20.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics